Aberle DR,Adams AM,Berg CD,Black WC,Clapp JD,Fagerstrom RM,Gareen IF,Gatsonis C,Marcus PM,Sicks JD .2011 .National Lung Screening Trial Research Team reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med, 365(5) : 395-409.
Andrew X Zhu ,Clin .2018 .REACH-2: A randomized, doubleblind, placebo-controlled phase 3 trial of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. Gastrointestinal (non-colorectal) Cancer. , 36(15) : 4003-4003.
Barrera L,Montes-Servín E,Barrera A,Ramírez-Tirado LA,Salinas-Parra F,Bañales-Méndez JL,SandovalRíos M,Arrieta O M .2015 .Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. , 26(2) : 428-435.
Chang CH,Hsiao CF,Yeh YM,Chang GC,Tsai YH,Chen YM,Huang MS,Chen HL,Li YJ,Yang PC,Chen CJ .2013 .Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int. J. Cancer., 132(9) : 1977-1985.
Escudier B,Eisen T,Stadler WM .2007 .Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med, 356(2) : 125-134.
Franco F and Provencio M,Garcia-CR F,Maurel J,Ayoub JP,Moore MJ,Cervantes A .2014 .An open-label phase II trial evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist., 19(4) : 350-51.
Gould MK .2014 .Clinical practice Lung-cancer screening with low-dose computed tomography. N Engl J Med, 371(19) : 1813-1820.
Han BH,Yang LL,Wang X,Yao LD .2018 .Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: A systematic review. Onco Targets Ther., 11 : 2121-2129.
Hellmann MD .2015 .Preliminary safety, pharmacokinetics and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced non-squamous non-small cell lung cancers. Clin. Lung Cancer, 16(6) : 514-522.
Hoffman PC,Mauer AM,Vokes EE .2000 .Lung cancer. , 355(9202) : 479-485.
Hu X .2018 .The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro. Biochem. Biophys. Res. Commun., 503(2) : 1123-1129.
Morabito A .2018 .Second-line treatment for advanced NSCLC without actionable mutations: Is immunotherapy the panacea for all patients? BMC Med. , 16(1) : 24.
Lu D,Shen J,Vil MD,Zhang H,Jimenez X,Bohlen P .2003 .Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem, 278(44) : 43496-43507.
Park JO .2016 .Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget., 7(46) : 75482-75491.
Qin S,Bai Y,Lim HY,Thongprasert S,Chao Y,Fan J .2013 .Randomized, multicenter, open-label trial of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol., 31(28) : 3501-3508.
Rosell R and Crino L .2002 .Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Semin Oncol., 29(2) : 23-29.
Shepherd FA .2001 .Phase II study of pemetrexed disodium, a multitargeted antifolate and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. , 92(3) : 595-600.
Siegel RL,Miller KD,Jemal A .2016 .. CA Cancer J. Clin., 66(1) : 7-30.
Torre LA,Bray F,Siegel RL,Ferlay J,Lortet-Tieulent J,Jemal A,Clin A .2012 .. Global cancer statistics, 65(2) : 87-108.
Wang Yongsheng .2012 .Erlotinib in the treatment of advanced non-small cell lung cancer: An update for clinicians. Ther. Adv. Med, 4(1) : 19-29.
Yoon HH,Bendell JC,Braiteh FS,Firdaus I,Philip PA .2016 .Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter phase II trial. , 27(12) : 2196-2203.
Zhu AX,Park JO,Ryoo BY,Yen CJ,Poon R,Pastorelli D R .2015 .Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. , 16(7) : 859-870.
Zhu Z,Hattori K,Zhang H,Jimenez X,Ludwig DL,Dias S DL .2003 .Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia, 17(3) : 604-611.